Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARS-17 Phase 2 dose-finding study of GSK3858279 in knee osteoarthritis pain
jRCT2031230411Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of GSK3858279 in knee osteoarthritis (OA) (5 arms), sponsored by GSK. Primary endpoint: Change from baseline at Week 12 in weekly average of average daily knee pain intensity (NRS). Started Nov 2023; status: completed.
02
Drugs
GSK3858279
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2031230411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230411.